Eletriptan

Eletriptan
Clinical data
Trade names	Relpax, Relert
AHFS/Drugs.com	Monograph
MedlinePlus	a603029
License data	US DailyMed: Eletriptan;
Pregnancy; category	AU: B1; ;
Routes of; administration	By mouth
ATC code	N02CC06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	50%
Metabolism	CYP3A4
Elimination half-life	4 hours
Identifiers
	IUPAC name 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(benzenesulfonyl)ethyl]-1H-indole;
CAS Number	143322-58-1 ; HBr: 177834-92-3 ;
PubChem CID	77993; HBr: 656631;
IUPHAR/BPS	40;
DrugBank	DB00216 ; HBr: DBSALT000884 ;
ChemSpider	70379 ; HBr: 570985 ;
UNII	22QOO9B8KI; HBr: M41W832TA3 ;
KEGG	D07887 ; HBr: D01973 ;
ChEBI	CHEBI:50922 ; HBr: CHEBI:61176 ;
ChEMBL	ChEMBL1510 ; HBr: ChEMBL1201003 ;
CompTox Dashboard (EPA)	DTXSID9046861 ;
ECHA InfoCard	100.167.337
Chemical and physical data
Formula	C22H26N2O2S
Molar mass	382.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC[C@@H]1Cc3c[nH]c4ccc(CCS(=O)(=O)c2ccccc2)cc34;
	InChI InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-137T56T ; Key:PWVXXGRKLHYWKM-LJQANCHMSA-N ;
	(what is this?) (verify)

Eletriptan, sold under the brand name Relpax and used in the form of eletriptan hydrobromide, is a second-generation triptan medication intended for treatment of migraine headaches.^[3]^[4] It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by Pfizer Inc.

^ "Relpax 20mg Film-Coated Tablets. - Summary of Product Characteristics (SmPC)". (emc). 3 July 2020. Retrieved 11 November 2020.
^ "Relpax- eletriptan hydrobromide tablet, film coated". DailyMed. 10 December 2019. Retrieved 11 November 2020.
^ Bhambri R, Mardekian J, Liu LZ, Schweizer E, Ramos E (2015). "A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine". International Journal of General Medicine. 8: 27–36. doi:10.2147/IJGM.S73673. PMC 4296958. PMID 25624770.
^ Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A, et al. (September 2016). "Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response". Therapeutic Advances in Neurological Disorders. 9 (5): 414–23. doi:10.1177/1756285616650619. PMC 4994780. PMID 27582896.

[Relpax_SmPC-1] "Relpax 20mg Film-Coated Tablets. - Summary of Product Characteristics (SmPC)". (emc). 3 July 2020. Retrieved 11 November 2020.

[Relpax_FDA_label-2] "Relpax- eletriptan hydrobromide tablet, film coated". DailyMed. 10 December 2019. Retrieved 11 November 2020.

[pmid25624770-3] Bhambri R, Mardekian J, Liu LZ, Schweizer E, Ramos E (2015). "A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine". International Journal of General Medicine. 8: 27–36. doi:10.2147/IJGM.S73673. PMC 4296958. PMID 25624770.

[pmid27582896-4] Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A, et al. (September 2016). "Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response". Therapeutic Advances in Neurological Disorders. 9 (5): 414–23. doi:10.1177/1756285616650619. PMC 4994780. PMID 27582896.

[1]

[2]

[3]

[4]